Effect of ginsenoside Rg3 on hepatocellular carcinoma

doi:10.3760/cma.j.issn.1007-1245.2022.07.006

Abstract

Abstract: According to the GLOBOCAN data in 2018, liver cancer ranked fourth in the number of malignant tumors and second in the number of deaths. It is recommended that patients with advanced hepatocellular carcinoma are treated with traditional Chinese medicine. Ginsenoside Rg3 is a rare ginsenoside of tetracyclic triterpenoid damarane type, and has 20 (R) and 20 (S) enantiomers. Shenyi capsule, a new anticancer drug with ginsenoside Rg3 monomer as the main component, was marketed in 2003, and is mainly used in the adjuvant treatment of lung cancer and liver cancer. Ginsenoside Rg3 has been proved to have good anti-liver cancer activity in vitro and in vivo. The mechanism of ginsenoside Rg3 against hepatocellular carcinoma is multiplex, including inducing apoptosis of hepatocellular carcinoma cells, inhibiting invasion and metastasis of hepatocellular carcinoma cells, inhibiting angiogenesis, reversing drug resistance, regulating autophagy, and enhancing immune function. In this review, the preclinical and clinical research progress of ginsenoside Rg3 in the treatment of hepatocellular carcinoma was reviewed so as to provide references for the subsequent research.

Key words: Ginsenoside Rg3, Primary hepatic carcinoma, Effect mechanism

摘要： 2018年GLOBOCAN数据显示，肝癌发病例数位居恶性肿瘤第4位，死亡例数位居第2位。中晚期肝癌患者推荐中医中药辅助肝癌的治疗。人参皂苷Rg3是一种四环三萜达玛烷型稀有人参皂苷，存在20（R）和20（S）两种对映异构体。以人参皂苷Rg3单体为主要成分的抗癌新药参一胶囊于2003年上市，主要应用于肺癌、肝癌的辅助治疗。人参皂苷Rg3体内外研究均证实其有良好的抗肝癌活性。人参皂苷Rg3抗肝癌的作用机制是多方面的，包括诱导肝癌细胞凋亡、调控自噬逆转耐药、抑制细胞侵袭及转移、抑制血管生成。本文就人参皂苷Rg3治疗肝癌的临床前及临床研究进展进行综述，以期对后续研究提供参考。

关键词: 人参皂苷Rg3, 原发性肝癌, 作用机制

Tang Linlin, Li Hongying, Liu Wenshan, Ding Chuanhua. Effect of ginsenoside Rg3 on hepatocellular carcinoma[J]. International Medicine and Health Guidance News, 2022, 28(7): 912-916.

唐琳琳, 李洪英, 刘文山, 丁传华. 人参皂苷Rg3抗肝癌作用研究进展[J]. 国际医药卫生导报, 2022, 28(7): 912-916.

References

[1] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019,144(8):1941-1953. DOI: 10.1002/ijc.31937.

[2] Zhang RR, Shao MY, Fu Y, et al. Network Meta-analysis of oral Chinese patent medicine for adjuvant treatment of primary liver cancer[J]. Zhongguo Zhong Yao Za Zhi, 2021,46(9):2333-2343. DOI: 10.19540/j.cnki.cjcmm. 20200721.501.

[3] Yue PY, Mak NK, Cheng YK, et al. Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides[J]. Chin Med, 2007,2:6. DOI: 10.1186/1749- 8546-2-6.

[4] Sun M, Ye Y, Xiao L, et al. Anticancer effects of ginsenoside Rg3 (Review)[J]. Int J Mol Med, 2017 ,39(3):507-518. DOI: 10.3892/ijmm.2017.2857.

[5] Kim WY, Kim JM, Han SB, et al. Steaming of ginseng at high temperature enhances biological activity[J]. J Nat Prod, 2000,63(12):1702-1704. DOI: 10.1021/np990152b.

[6] Kwok HH, Guo GL, Lau JK, et al. Stereoisomers ginsenosides-20(S)-Rg₃ and -20(R)-Rg₃ differentially induce angiogenesis through peroxisome proliferator-activated receptor-gamma[J]. Biochem Pharmacol, 2012,83(7):893-902. DOI: 10.1016/j.bcp. 2011.12.039.

[7] Teng S, Wang Y, Li P, et al. Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells[J]. Mol Med Rep, 2017,15(4):2029-2038. DOI: 10.3892/mmr.2017.6255.

[8] Cheong JH, Kim H, Hong MJ, et al. Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 in HepG2 cells: disparity in cytotoxicity and autophagy-inducing effects due to 20(S)-epimers[J]. Biol Pharm Bull, 2015,38(1):102-108. DOI: 10.1248/bpb.b14-00603.

[9] Kang DI, Lee JY, Yang JY, et al. Evidence that the tertiary structure of 20(S)-ginsenoside Rg(3) with tight hydrophobic packing near the chiral center is important for Na(+) channel regulation[J]. Biochem Biophys Res Commun, 2005,333(4):1194-1201. DOI: 10.1016/j.bbrc.2005.06.026.

[10] Park HM, Kim SJ, Kim JS, et al. Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced apoptosis in hepatoma cells through mitochondrial signaling pathways[J]. Food Chem Toxicol, 2012,50(8):2736-2741. DOI: 10.1016/j.fct.2012.05.027.

[11] Li X, Tsauo J, Geng C, et al. Ginsenoside Rg3 decreases NHE1 expression via Inhibiting EGF-EGFR-ERK1/2-HIF-1 α pathway in hepatocellular carcinoma: a novel antitumor mechanism[J]. Am J Chin Med, 2018,46(8):1915-1931. DOI: 10.1142/S0192415X18500969.

[12] Sun MY, Song YN, Zhang M, et al. Ginsenoside Rg3 inhibits the migration and invasion of liver cancer cells by increasing the protein expression of ARHGAP9[J]. Oncol Lett, 2019,17(1):965-973. DOI: 10.3892/ol.2018.9701.

[13] Hu S, Zhu Y, Xia X, et al. Ginsenoside Rg3 prolongs survival of the orthotopic hepatocellular carcinoma model by inducing apoptosis and inhibiting angiogenesis[J]. Anal Cell Pathol (Amst), 2019,2019:3815786. DOI: 10.1155/2019/3815786.

[14] Wu R, Ru Q, Chen L, et al. Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice[J]. J Food Sci, 2014,79(7):H1430-1435. DOI: 10.1111/1750-3841.12518.

[15] Shan K, Wang Y, Hua H, et al. Ginsenoside Rg3 combined with oxaliplatin inhibits the proliferation and promotes apoptosis of hepatocellular carcinoma cells via downregulating PCNA and cyclin D1[J]. Biol Pharm Bull, 2019,42(6):900-905. DOI: 10.1248/bpb.b18-00852.

[16] Kim DG, Jung KH, Lee DG, et al. 20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin[J]. Oncotarget, 2014,5(12):4438-4451. DOI: 10.18632/oncotarget.2034.

[17] Jiang JW, Chen XM, Chen XH, et al. Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via intrinsic apoptotic pathway[J]. World J Gastroenterol, 2011,17(31):3605-3613. DOI: 10.3748/wjg.v17.i31.3605.

[18] Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic strategies for hepatocellular carcinoma: 2020 update[J]. Cancers (Basel), 2020,12(4):791. DOI: 10.3390/cancers12040791.

[19] Han Z, Dong Y, Lu J, et al. Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application[J]. Am J Cancer Res, 2021,11(8):3777-3793.

[20] Zhou B, Wang J, Yan Z. Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model[J]. Onco Targets Ther, 2014,7:1945-1954. DOI: 10.2147/OTT.S69830.

[21] Yu Y, Zhang C, Liu L, et al. Hepatic arterial administration of ginsenoside Rg3 and transcatheter arterial embolization for the treatment of VX2 liver carcinomas[J]. Exp Ther Med, 2013,5(3):761-766. DOI: 10.3892/etm.2012.873.

[22] Ren Z, Chen X, Hong L, et al. Nanoparticle conjugation of ginsenoside Rg3 inhibits hepatocellular carcinoma development and metastasis[J]. Small, 2020,16(2):e1905233. DOI: 10.1002/smll.201905233.

[23] Lu SL, Wang YH, Liu GF, et al. Graphene oxide nanoparticle-loaded ginsenoside rg3 improves photodynamic therapy in inhibiting malignant progression and stemness of osteosarcoma[J]. Front Mol Biosci, 2021,8:663089. DOI: 10.3389/fmolb.2021.663089.

[24] Yu H, Teng L, Meng Q, et al. Development of liposomal ginsenoside Rg3: formulation optimization and evaluation of its anticancer effects[J]. Int J Pharm, 2013,450(1-2):250-258. DOI: 10.1016/j.ijpharm.2013.04.065.

[25] 付淑凤.人参皂苷Rg3-mPEG-PLLA载药胶束的构建与药效学评价[J].中药材,2019,42(8):1860-1865.DOI:10.13863/j.issn1001-4454.2019.08.031.

[26] 杨鸿国. 人参皂苷Rg3在原发性肝癌合并门静脉癌栓手术后预防复发转移的临床研究[D].杭州:浙江中医药大学,2017.

[27] Zhou B, Yan Z, Liu R, et al. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma[J]. Radiology, 2016,280(2):630-639. DOI: 10.1148/radiol.2016150719.

[28] Zhang F, Li M, Wu X, et al. 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway[J]. Drug Des Devel Ther, 2015 ,9:3969-3987. DOI: 10.2147/DDDT.S84527.

[29] Wang JH, Nao JF, Zhang M, et al. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways[J]. Tumour Biol, 2014,35(12):11985-11994. DOI: 10.1007/s13277-014-2497-5.

[30] Bian S, Zhao Y, Li F, et al. 20(S)-ginsenoside Rg3 promotes hela cell apoptosis by regulating autophagy[J]. Molecules, 2019,24(20):3655. DOI: 10.3390/molecules24203655.

[31] Zhang C, Liu L, Yu Y, et al. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells[J]. Mol Med Rep, 2012,5(5):1295-1298. DOI: 10.3892/mmr.2012.808.

[32] Li Y, Lu J, Bai F, et al. Ginsenoside Rg3 suppresses proliferation and induces apoptosis in human osteosarcoma[J]. Biomed Res Int, 2018,2018:4306579. DOI: 10.1155/2018/4306579.

[33] Yang X, Wang D, Dong W, et al. Expression and modulation of Na(+) /H(+) exchanger 1 gene in hepatocellular carcinoma: a potential therapeutic target[J]. J Gastroenterol Hepatol, 2011,26(2):364-370. DOI: 10.1111/j. 1440-1746.2010.06382.x.

[34] Li X, Tsauo J, Geng C, et al. Ginsenoside Rg3 decreases NHE1 expression via inhibiting EGF-EGFR-ERK1/2-HIF-1 α pathway in hepatocellular carcinoma: a novel antitumor mechanism[J]. Am J Chin Med, 2018,46(8):1915-1931. DOI: 10.1142/S0192415X18500969.

[35] Lee JY, Jung KH, Morgan MJ, et al. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells[J]. Mol Cancer Ther, 2013,12(3):274-285. DOI: 10.1158/1535-7163.MCT-12-0054.

[36] Bian S, Zhao Y, Li F, et al. 20(S)-ginsenoside Rg3 promotes heLa cell apoptosis by regulating autophagy[J]. Molecules,2019, 24(20):3655. DOI: 10.3390/molecules24203655.

[37] Mao X, Jin Y, Feng T, et al. Ginsenoside Rg3 inhibits the growth of osteosarcoma and attenuates metastasis through the wnt/β-Catenin and EMT signaling pathway[J]. Evid Based Complement Alternat Med, 2020,2020:6065124. DOI: 10.1155/2020/6065124.

[38] Liu T, Zhao L, Hou H, et al. Ginsenoside 20(S)-Rg3 suppresses ovarian cancer migration via hypoxia-inducible factor 1 alpha and nuclear factor-kappa B signals[J]. Tumour Biol, 2017,39(5):1010428317692225. DOI: 10.1177/1010428317692225.

[39] Keung MH, Chan LS, Kwok HH, et al. Role of microRNA-520h in 20(R)-ginsenoside-Rg3-mediated angiosuppression[J]. J Ginseng Res, 2016,40(2):151-159. DOI: 10.1016/j.jgr.2015.07.002.